[ET Net News Agency, 4 June 2021] Hansoh Pharmaceutical Group Company Limited (03692)
said "Erlotinib Hydrochloride Tablets" developed by Jiangsu Hansoh Pharmaceutical Group
Co., Ltd., a subsidiary of the company, has been granted drug registration approval by the
National Medical Products Administration of the People's Republic of China.
The product is an oncology drug indicated for the treatment of patients with locally
advanced or late-stage metastatic non-small cell lung cancer (NSCLC) whose tumours have
epidermal growth factor receptor (EGFR) sensitizing mutations, and receiving first-line
treatment, maintenance treatment, or second or greater line treatment after progression at
least one prior chemotherapy regimen. (RC)